A 24 week phase 2b dose range finding study of RTB101 alone or in combination with RAD001 on the incidence of RTI in elderly subjects at increased risk of RTI-related morbidity and mortality.
Phase of Trial: Phase II
Latest Information Update: 09 May 2017
At a glance
- Drugs RTB101 (Primary) ; Everolimus
- Indications Immunodeficiency disorders
- Focus Therapeutic Use
- 09 May 2017 According to a PureTech media release, results from this study anticipated in the second half of 2018.
- 09 May 2017 Status changed from planning to recruiting, according to a PureTech media release.
- 21 Apr 2017 New trial record